compugen - CGEN
CGEN
Close Chg Chg %
2.48 -0.02 -0.81%
Closed Market
2.46
-0.02 (0.81%)
Volume: 206.98K
Last Updated:
Sep 10, 2026, 4:00 PM EDT
Company Overview: compugen - CGEN
CGEN Key Data
| Open $2.48 | Day Range 2.44 - 2.51 |
| 52 Week Range 1.30 - 3.24 | Market Cap $242.50M |
| Shares Outstanding 94.73M | Public Float 94.37M |
| Beta 2.79 | Rev. Per Employee N/A |
| P/E Ratio 6.91 | EPS $0.37 |
| Yield 0.00% | Dividend N/A |
| EX-DIVIDEND DATE | SHORT INTEREST N/A |
| AVERAGE VOLUME 314.24K |
CGEN Performance
| 1 Week | -5.02% | ||
| 1 Month | 2.07% | ||
| 3 Months | 20.59% | ||
| 1 Year | 83.58% | ||
| 5 Years | -60.95% |
CGEN Analyst Ratings
- Sell
- Under
- Hold
- Over
- Buy
Number of Ratings
5
Full Ratings ➔
About compugen - CGEN
Compugen Ltd. engages in the research, development, and commercialization of therapeutic and diagnostic biomarker product candidates including proteins and monoclonal antibodies. It focuses on research and development on immuno-oncology and autoimmune diseases. The company was founded by Eli Mintz, Simchon Faigler, and Amir Natan on February 10, 1993 and is headquartered in Holon, Israel.
CGEN At a Glance
Compugen Ltd.
Azrieli Center
Holon, Tel Aviv 58858
| Phone | 972-3-765-8585 | Revenue | 72.76M | |
| Industry | Biotechnology | Net Income | 35.34M | |
| Sector | Health Technology | 2025 Sales Growth | 161.14% | |
| Fiscal Year-end | 12 / 2026 | Employees | 75 | |
| View SEC Filings |
CGEN Valuation
| P/E Current | 6.911 |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | 4.062 |
| Price to Sales Ratio | 1.973 |
| Price to Book Ratio | 1.408 |
| Price to Cash Flow Ratio | 4.54 |
| Enterprise Value to EBITDA | 0.027 |
| Enterprise Value to Sales | 0.012 |
| Total Debt to Enterprise Value | 3.454 |
CGEN Efficiency
| Revenue/Employee | 970,186.667 |
| Income Per Employee | 471,240.00 |
| Receivables Turnover | 247.497 |
| Total Asset Turnover | 0.535 |
CGEN Liquidity
| Current Ratio | 6.558 |
| Quick Ratio | 6.558 |
| Cash Ratio | 6.453 |
CGEN Profitability
| Gross Margin | 87.286 |
| Operating Margin | 43.052 |
| Pretax Margin | 48.646 |
| Net Margin | 48.572 |
| Return on Assets | 26.00 |
| Return on Equity | 44.839 |
| Return on Total Capital | 33.44 |
| Return on Invested Capital | 43.486 |
CGEN Capital Structure
| Total Debt to Total Equity | 2.881 |
| Total Debt to Total Capital | 2.801 |
| Total Debt to Total Assets | 1.887 |
| Long-Term Debt to Equity | 2.374 |
| Long-Term Debt to Total Capital | 2.308 |
- Income Statement
- Balance Sheet
- Cash Flow Statement
Annual Financials for Compugen - CGEN
Collapse All in section
| All values USD millions. | 2022 | 2023 | 2024 | 2025 | 5-year trend |
|---|---|---|---|---|---|
Sales/Revenue
| 7.50M | 33.46M | 27.86M | 72.76M | |
Sales Growth
| +25.00% | +346.12% | -16.72% | +161.14% | |
Cost of Goods Sold (COGS) incl D&A
| 1.46M | 2.48M | 7.93M | 9.25M | |
COGS excluding D&A
| - | - | - | - | - |
Depreciation & Amortization Expense
| 482.00K | 476.00K | 486.00K | 475.00K | |
Depreciation
| 482.00K | 476.00K | 486.00K | 475.00K | |
Amortization of Intangibles
| - | - | - | - | - |
COGS Growth
| +27.70% | +70.21% | +219.76% | +16.66% | |
Gross Income
| 6.04M | 30.98M | 19.93M | 63.51M | |
Gross Income Growth
| +24.37% | +412.64% | -35.65% | +218.62% | |
Gross Profit Margin
| +80.57% | +92.59% | +71.54% | +87.29% |
| 2022 | 2023 | 2024 | 2025 | 5-year trend | |
|---|---|---|---|---|---|
SG&A Expense
| 41.42M | 43.97M | 34.83M | 32.19M | |
Research & Development
| 30.65M | 34.47M | 24.81M | 22.76M | |
Other SG&A
| 10.77M | 9.50M | 10.02M | 9.43M | |
SGA Growth
| +3.72% | +6.17% | -20.80% | -7.58% | |
Other Operating Expense
| - | - | - | - | - |
Unusual Expense
| - | - | - | - | - |
EBIT after Unusual Expense
| (35.37M) | (12.99M) | (14.89M) | 31.33M | |
Non Operating Income/Expense
| 1.77M | 3.24M | 5.18M | 4.07M | |
Non-Operating Interest Income
| 1.44M | 3.24M | 5.24M | 4.41M | |
Equity in Earnings of Affiliates
| - | - | - | - | - |
Interest Expense
| - | - | 27.00K | 31.00K | - |
Interest Expense Growth
| - | +8.00% | +14.81% | -100.00% | |
Gross Interest Expense
| - | - | 27.00K | 31.00K | - |
Interest Capitalized
| - | - | - | - | - |
Pretax Income
| (33.64M) | (9.78M) | (9.71M) | 35.40M | |
Pretax Income Growth
| +1.66% | +70.91% | +0.77% | +464.58% | |
Pretax Margin
| -448.48% | -29.24% | -34.84% | +48.65% | |
Income Tax
| 58.00K | 8.97M | 4.52M | 54.00K | |
Income Tax - Current - Domestic
| - | - | - | - | - |
Income Tax - Current - Foreign
| - | - | - | - | - |
Income Tax - Deferred - Domestic
| - | - | - | - | - |
Income Tax - Deferred - Foreign
| - | - | - | - | - |
Income Tax Credits
| - | - | - | - | - |
Equity in Earnings of Affiliates
| - | - | - | - | - |
Other After Tax Income (Expense)
| - | - | - | - | - |
Consolidated Net Income
| (33.69M) | (18.75M) | (14.23M) | 35.34M | |
Minority Interest Expense
| - | - | - | - | - |
Net Income
| (33.69M) | (18.75M) | (14.23M) | 35.34M | |
Net Income Growth
| +1.49% | +44.34% | +24.12% | +348.35% | |
Net Margin Growth
| -449.25% | -56.05% | -51.07% | +48.57% | |
Extraordinaries & Discontinued Operations
| - | - | - | - | - |
Discontinued Operations
| - | - | - | - | - |
Net Income After Extraordinaries
| (33.69M) | (18.75M) | (14.23M) | 35.34M | |
Preferred Dividends
| - | - | - | - | - |
Net Income Available to Common
| (33.69M) | (18.75M) | (14.23M) | 35.34M | |
EPS (Basic)
| -0.3893 | -0.214 | -0.159 | 0.3783 | |
EPS (Basic) Growth
| +4.16% | +45.03% | +25.70% | +337.92% | |
Basic Shares Outstanding
| 86.56M | 87.63M | 89.53M | 93.43M | |
EPS (Diluted)
| -0.3893 | -0.214 | -0.159 | 0.3767 | |
EPS (Diluted) Growth
| +4.16% | +45.03% | +25.70% | +336.92% | |
Diluted Shares Outstanding
| 86.56M | 87.63M | 89.53M | 93.82M | |
EBITDA
| (34.89M) | (12.52M) | (14.40M) | 31.80M | |
EBITDA Growth
| -0.81% | +64.13% | -15.09% | +320.76% | |
EBITDA Margin
| -465.23% | -37.41% | -51.70% | +43.70% |
Snapshot
| Average Recommendation | BUY | Average Target Price | 4.60 | |
| Number of Ratings | 5 | Current Quarters Estimate | -0.08 | |
| FY Report Date | 09 / 2026 | Current Year's Estimate | -0.28 | |
| Last Quarter’s Earnings | -0.07 | Median PE on CY Estimate | N/A | |
| Year Ago Earnings | 0.38 | Next Fiscal Year Estimate | -0.276 | |
| Median PE on Next FY Estimate | N/A |
Earnings Per Share
| This Quarter | Next Quarter | This Fiscal | Next Fiscal | |
|---|---|---|---|---|
| # of Estimates | 5 | 5 | 5 | 5 |
| Mean Estimate | -0.08 | -0.05 | -0.28 | -0.28 |
| High Estimates | -0.06 | 0.02 | -0.19 | 0.11 |
| Low Estimate | -0.10 | -0.10 | -0.35 | -0.41 |
| Coefficient of Variance | -19.76 | -123.55 | -25.63 | -79.36 |
Analysts Recommendations
| Current | 1 Month Ago | 3 Months Ago | |
|---|---|---|---|
| BUY | 5 | 5 | 5 |
| OVERWEIGHT | 0 | 0 | 0 |
| HOLD | 0 | 0 | 0 |
| UNDERWEIGHT | 0 | 0 | 0 |
| SELL | 0 | 0 | 0 |
| MEAN | Buy | Buy | Buy |
SEC Filings for Compugen - CGEN
| Filing Date | Type | Category | Amended |
|---|---|---|---|
| No results | |||
Insider Actions for Compugen - CGEN
| Date | Name | Shares | Transaction | Value |
|---|---|---|---|---|
| Jul 14, 2026 | Zurit Levine SVP, Business Development | 31,250 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 Non-derivative transaction at $0.83 per share | 25,937.50 |
| Jul 14, 2026 | Zurit Levine SVP, Business Development | 29,375 | Open market or private sale of non-derivative or derivative security Non-derivative transaction at $2.5 per share | 73,437.50 |
| Jul 14, 2026 | Zurit Levine SVP, Business Development | 3,750 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
| Apr 28, 2026 | Eran Ophir President and CEO; Director | 16,375 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 Non-derivative transaction at $0.83 per share | 13,591.25 |
| Apr 28, 2026 | Eran Ophir President and CEO; Director | 11,375 | Open market or private sale of non-derivative or derivative security Non-derivative transaction at $3.2 per share | 36,400.00 |
| Apr 28, 2026 | Eran Ophir President and CEO; Director | 14,375 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
| Apr 16, 2026 | Zurit Levine SVP, Business Development | 5,625 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
| Apr 16, 2026 | Zurit Levine SVP, Business Development | 56,000 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
| Apr 10, 2026 | Zurit Levine SVP, Business Development | 11,125 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
| Apr 10, 2026 | Zurit Levine SVP, Business Development | 6,750 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
| Apr 10, 2026 | Zurit Levine SVP, Business Development | 58,000 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |